AIM
EDIT icon

Acrospire Investment Management’s Editas Medicine EDIT Stock Holding History

Acrospire Investment Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-600
Closed -$8K – 2261
2016
Q3 		$8K Sell
600
-600
-50% -$12.3K 0.01% 1747
2016
Q2 		$29K Buy
1,200
+400
+50% +$13.5K 0.02% 1398
2016
Q1 		$28K Buy
+800
New +$21K 0.02% 1351

Other funds holding EDIT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Acrospire Investment Management's EDIT Position: Q4 2016 in Review

Acrospire Investment Management sold out of Editas Medicine (EDIT) in Q4 2016, closing a stake of 600 shares — an estimated $8K sold.

Acrospire Investment Management first reported a position in EDIT in Q1 2016 and held it in 3 quarters. The position peaked at $29K in Q2 2016. 84 funds tracked by Wall St. Rank hold EDIT as of Q4 2016.

  • Acrospire Investment Management reported no remaining Editas Medicine position as of Q4 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 600 Editas Medicine shares in Q4 2016, an estimated $8K.
  • Acrospire Investment Management first reported a position in Editas Medicine in Q1 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Editas Medicine position peaked at $29K in Q2 2016.
  • 84 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2016.

Based on Acrospire Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.